How to Get Tirzepatide Covered by Insurance: The Complete 2026 Approval Process

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide insurance coverage requires either a type 2 diabetes diagnosis (Mounjaro) or obesity with BMI over 30 (Zepbound), plus documented medical necessity through prior authorization in 73% of commercial plans
• The prior authorization process takes 3 to 14 business days and requires specific lab values, medication history, and sometimes documented diet/exercise attempts
• When insurance denies coverage, a structured three-level appeal process exists, with 34% of first-level appeals succeeding based on 2025 industry data
• Patients whose insurance won't cover tirzepatide pay $940 to $1,200 monthly out-of-pocket, making compounded tirzepatide ($179 to $299 monthly) the most common alternative

Direct answer (40-60 words)

Getting tirzepatide covered by insurance requires a qualifying diagnosis (type 2 diabetes or obesity), a prescription from a licensed provider, and prior authorization approval from your insurance company. The process involves submitting medical records, lab results, and documentation of previous weight-loss attempts. Approval rates vary by plan but average 62% for diabetes and 41% for weight loss.

Table of contents

1. The two FDA-approved paths to tirzepatide coverage
2. What most articles get wrong about insurance requirements
3. The prior authorization process: what your provider actually submits
4. Timeline: how long each step takes in 2026
5. The six documentation requirements that determine approval
6. Real approval scenarios across five major insurance types
7. What to do when your PA is denied (the three-level appeal system)
8. The Lilly savings card: who qualifies and how it works
9. When insurance will never cover tirzepatide (and what to do instead)
10. The compounded tirzepatide alternative for denied patients
11. How to check your specific coverage in 10 minutes
12. FAQ

The two FDA-approved paths to tirzepatide coverage

Tirzepatide exists as two separate brand-name medications with different FDA approvals and different insurance coverage rules.

Path 1: Mounjaro for type 2 diabetes. FDA-approved May 2022. Indicated for improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Insurance coverage follows diabetes medication rules. Most commercial plans cover Mounjaro on specialty tier (Tier 4 or Tier 5) with prior authorization. Medicare Part D plans cover Mounjaro for diabetes but not for weight loss.

Path 2: Zepbound for chronic weight management. FDA-approved November 2023. Indicated for chronic weight management in adults with obesity (BMI over 30) or overweight (BMI over 27) with at least one weight-related comorbidity. Insurance coverage follows weight-loss medication rules, which are significantly more restrictive. Many commercial plans exclude weight-loss medications entirely. Medicare explicitly does not cover weight-loss medications by federal law.

The molecule is identical. The indication determines coverage. A prescription written for "tirzepatide for weight loss" when you have type 2 diabetes will be denied because the correct product is Mounjaro, not Zepbound. A prescription for "Mounjaro for weight loss" when you don't have diabetes will be denied because Mounjaro isn't FDA-approved for that use.

Your provider must match the product to your diagnosis. This is the single most common error in tirzepatide insurance claims.

What most articles get wrong about insurance requirements

Most published guides claim "you need a BMI over 30 to get tirzepatide covered." This is wrong in a specific, consequential way.

BMI over 30 qualifies you for Zepbound (the weight-loss formulation), but most commercial insurance plans don't cover weight-loss medications at all, regardless of BMI. A 2025 survey by the Kaiser Family Foundation found that only 28% of employer-sponsored health plans covered GLP-1 medications for weight loss, down from 31% in 2024 as employers dropped coverage due to cost (Kaiser Family Foundation, 2025).

The path with higher approval rates is the diabetes path. If you have type 2 diabetes and a prescription for Mounjaro, your approval odds are roughly 62% across commercial plans. If you have obesity without diabetes and a prescription for Zepbound, your approval odds drop to 41%, and that's only among the minority of plans that cover weight-loss drugs at all (IQVIA Institute, 2025).

The practical implication: patients with both obesity and prediabetes (A1C 5.7% to 6.4%) often get denied for Zepbound because they don't have diabetes, then get denied for Mounjaro because their A1C isn't high enough to meet the type 2 diabetes threshold. They fall into a coverage gap despite clear medical need.

The workaround some providers use: document cardiovascular risk factors (hypertension, dyslipidemia, family history) and frame the prescription as diabetes prevention in a high-risk patient. This increases PA approval rates but requires the provider to build a specific clinical narrative in the prior authorization paperwork.

The prior authorization process: what your provider actually submits

Prior authorization (PA) is a request your provider sends to your insurance company asking for approval to prescribe a medication. For tirzepatide, the PA is not optional. It's required by 73% of commercial plans and 89% of Medicare Part D plans (MMIT, 2025).

What the PA form asks for:

1. Diagnosis code. ICD-10 code for type 2 diabetes (E11.9) or obesity (E66.01, E66.09). The diagnosis must match the product (Mounjaro for diabetes, Zepbound for weight).

1. Current labs. A1C, fasting glucose, lipid panel, liver function tests. Most plans require labs from the past 90 days. For diabetes PAs, A1C must typically be over 7.0% despite other medications. For weight-loss PAs, BMI calculation and weight history.

1. Medication history. Documentation that you've tried and failed (or have contraindications to) at least one other diabetes medication (for Mounjaro) or weight-loss intervention (for Zepbound). "Failed" means inadequate response after at least 90 days at therapeutic dose, documented side effects, or medical contraindication.

1. Comorbidities. Hypertension, dyslipidemia, cardiovascular disease, sleep apnea, NAFLD, PCOS. Each comorbidity strengthens the medical necessity argument.

1. Lifestyle intervention documentation. Some plans require proof of diet and exercise attempts. This can be as simple as provider notes documenting nutrition counseling and exercise recommendations over the past 6 months.

1. Provider attestation. A statement that the provider believes tirzepatide is medically necessary and that the patient has been counseled on risks, benefits, and alternatives.

The PA is submitted electronically through the insurance company's portal or by fax. The insurance company's pharmacy benefit manager (PBM) reviews the submission against their coverage criteria.

Timeline: how long each step takes in 2026

Day 0: Office visit. You see a provider. The provider writes a prescription for tirzepatide and submits the prior authorization request. Some offices submit the PA during your visit. Others submit within 24 to 48 hours.

Day 1-3: Initial review. The PBM receives the PA and assigns it to a reviewer. Automated systems check for missing information. If anything is missing, the PBM sends a request for additional information back to the provider. This adds 3 to 7 days.

Day 3-7: Clinical review. A pharmacist or nurse at the PBM reviews your medical records against the plan's coverage criteria. If the criteria are clearly met, approval happens here. If borderline, the case escalates to a physician reviewer.

Day 7-14: Physician review (if needed). For complex cases, a physician at the PBM reviews the PA. This physician is typically not a specialist in endocrinology or obesity medicine. They apply the plan's written criteria. If the criteria are met, approval. If not, denial.

Day 14: Decision. You and your provider receive the decision. Approval means you can fill the prescription. Denial means you can appeal, pay cash, or explore alternatives.

The median time from PA submission to decision is 8 business days for tirzepatide across major PBMs (Express Scripts, CVS Caremark, OptumRx) based on 2025 data (MMIT, 2025). Urgent PAs (marked urgent by the provider) are supposed to be reviewed within 72 hours, but this is inconsistently enforced.

The six documentation requirements that determine approval

Based on analysis of PA approval and denial letters from five major PBMs, six specific documentation elements predict approval.

1. A1C over the plan's threshold (for diabetes PAs). Most plans require A1C over 7.0%. Some require over 7.5%. If your A1C is 6.8%, you'll likely be denied even if you have diagnosed type 2 diabetes. The PA should include the actual lab value and date.

2. Trial of metformin (for diabetes PAs). Nearly all plans require documented trial of metformin for at least 90 days before approving tirzepatide. If you're metformin-intolerant (GI side effects), the provider must document the intolerance. If you have a contraindication (renal impairment, lactic acidosis risk), the provider must document the contraindication with supporting labs.

3. BMI documentation with date (for weight-loss PAs). The PA must include your current weight, height, calculated BMI, and the date measured. Many denials happen because the BMI was calculated from patient-reported weight rather than measured in-office weight. Use the most recent measured weight.

4. Comorbidity documentation (for weight-loss PAs). For Zepbound, plans typically require BMI over 30, or BMI 27 to 30 with at least one weight-related comorbidity. Qualifying comorbidities: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease. The comorbidity must be documented with a diagnosis code and supporting evidence (BP readings, lipid panel, sleep study).

5. Previous weight-loss attempts (for weight-loss PAs). Many plans require documentation of previous weight-loss attempts. This can include provider-supervised diet programs, commercial programs (Weight Watchers, Noom), or previous weight-loss medications. The documentation should show dates, duration, and outcomes. "Patient reports trying multiple diets" is often insufficient. "Patient enrolled in medically supervised low-calorie diet program from March to September 2025, lost 8 lbs then plateaued" is sufficient.

6. Cardiovascular risk documentation. For both diabetes and weight-loss PAs, documented cardiovascular risk strengthens the case. ASCVD risk score, family history of early MI, existing CAD, stroke history. Tirzepatide has demonstrated cardiovascular benefits in clinical trials, and some plans give preferential approval to high-CV-risk patients (Sattar et al., NEJM 2024).

A PA that includes all six relevant elements (relevant to the indication) has an 81% approval rate. A PA missing two or more elements has a 34% approval rate based on patterns we observe in FormBlends provider network data.

Real approval scenarios across five major insurance types

Scenario 1: Large employer PPO (UnitedHealthcare, Aetna, Cigna). Patient is 52, type 2 diabetes for 6 years, A1C 8.1% on metformin 2000 mg daily. BMI 34. Hypertension controlled on lisinopril. Provider submits PA for Mounjaro with 90-day metformin trial documented, recent A1C, and CV risk factors. Approved in 5 business days. Tier 4 copay is $150 per month. Lilly savings card reduces copay to $25.

Scenario 2: Marketplace silver plan (BlueCross BlueShield). Patient is 38, no diabetes, BMI 32, no other diagnoses. Provider submits PA for Zepbound. Plan's formulary excludes all weight-loss medications. Denied within 24 hours with explanation: "Weight-loss medications are not a covered benefit under this plan." Appeal is unlikely to succeed because the exclusion is plan-wide, not patient-specific. Patient switches to compounded tirzepatide at $249/month.

Scenario 3: Medicare Part D. Patient is 68, type 2 diabetes, A1C 7.8%, BMI 29. Provider submits PA for Mounjaro. Medicare Part D covers Mounjaro for diabetes. Approved in 11 business days. Specialty tier copay is $400 per month. Lilly savings card does not apply to Medicare patients (federal anti-kickback statute). Patient cannot afford $400/month, switches to insulin.

Scenario 4: Medicaid (state-dependent). Patient is 44, type 2 diabetes, A1C 9.2%, BMI 36, on Medicaid in Texas. Texas Medicaid covers Mounjaro with PA. PA requires trial of metformin plus one other oral agent (sulfonylurea or DPP-4 inhibitor). Patient has tried metformin only. PA denied. Provider adds glipizide, patient tries for 90 days, A1C remains 8.9%. Second PA submitted, approved. $0 copay.

Scenario 5: High-deductible health plan (HDHP). Patient is 29, BMI 31, prediabetes (A1C 6.1%), PCOS, trying to conceive. Provider submits PA for Zepbound citing obesity and PCOS. Plan covers weight-loss medications but requires BMI over 30 (met) and trial of lifestyle intervention (not documented). PA denied. Provider resubmits with 6 months of nutrition counseling notes. Approved. Patient must meet $5,000 deductible first, so pays full negotiated rate ($1,047/month) until deductible met, then 20% coinsurance ($209/month).

The pattern: diabetes PAs with proper documentation succeed more often than weight-loss PAs. Plans that exclude weight-loss medications entirely cannot be appealed on medical necessity grounds.

What to do when your PA is denied (the three-level appeal system)

A PA denial is not final. Insurance companies are required by law to offer an appeals process.

Level 1: Peer-to-peer review (provider-initiated). Your provider requests a phone call with the insurance company's reviewing physician. The two physicians discuss your case. Your provider explains why tirzepatide is medically necessary despite the denial. The insurance physician can overturn the denial on the call. This is the fastest appeal route. Success rate: 34% based on 2025 aggregate data from CoverMyMeds (CoverMyMeds, 2025).

Level 2: Formal written appeal (provider or patient-initiated). Your provider (or you) submits a written appeal with additional documentation. This might include published studies showing tirzepatide's efficacy for your specific condition, letters from specialists, or documentation of failed alternatives. The appeal goes to a different reviewer than the original denial. Turnaround time: 15 to 30 days. Success rate: 22%.

Level 3: External review (patient-initiated). If the internal appeal is denied, you can request an external review by an independent third party. This is a legal right under the Affordable Care Act. The external reviewer is not employed by your insurance company. They review the case based on medical evidence and coverage law. Turnaround time: 30 to 60 days. Success rate: 18%, but this varies widely by state.

When to appeal vs. when to move on:

Appeal if:

• The denial reason is "insufficient documentation" and you can provide the missing documentation.
• The denial reason is "medication not tried" and you have tried the medication but it wasn't documented.
• Your case involves a clear medical necessity (very high A1C, multiple failed medications, significant comorbidities).

Move on if:

• The denial reason is "not a covered benefit" (the plan excludes the entire drug category).
• You've exhausted all three appeal levels.
• The appeal timeline is longer than you can wait for treatment.

FormBlends clinical pattern: Among patients who come to us after insurance denial, 67% were denied for weight-loss indications on plans that don't cover weight-loss medications. These denials are structural, not medical. The remaining 33% were denied for missing documentation, and about half of those would likely succeed on appeal if their provider resubmitted with complete records.

The Lilly savings card: who qualifies and how it works

Eli Lilly offers a manufacturer copay assistance program for both Mounjaro and Zepbound.

Eligibility:

• Commercial insurance that covers the medication (Mounjaro or Zepbound)
• Prescription written for FDA-approved indication (diabetes for Mounjaro, weight management for Zepbound)
• Not enrolled in Medicare, Medicaid, TRICARE, or any government-funded program
• U.S. resident

What it does:

• Reduces copay to as low as $25 per month for Mounjaro
• Reduces copay to as low as $25 per month for Zepbound (as of Q1 2026, Lilly extended Zepbound savings card benefits to match Mounjaro)
• Maximum savings of approximately $150 per fill
• Valid for up to 24 fills

Who's excluded:

• Medicare and Medicaid patients (federal anti-kickback statute prohibits manufacturer copay assistance for government programs)
• Patients whose insurance doesn't cover the medication at all (the card reduces a copay, it doesn't create coverage)
• Patients paying cash without insurance

How to use it: Download the card from LillyDirect.com or get a physical card from your provider. Present the card with your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your out-of-pocket cost.

The savings card is the reason most insured patients with PA approval pay $25 to $50 per month for tirzepatide instead of $150 to $400. It's the single most important cost-reduction tool for commercially insured patients.

When insurance will never cover tirzepatide (and what to do instead)

Some insurance situations have zero chance of tirzepatide coverage, no matter how strong your medical case.

Situation 1: Your plan has a blanket exclusion for weight-loss medications. About 72% of commercial plans exclude GLP-1 receptor agonists for weight loss as of 2026 (KFF, 2025). If your plan's summary of benefits says "weight-loss medications: not covered," no amount of documentation will change that. The exclusion is contractual.

What to do: If you have type 2 diabetes, get a prescription for Mounjaro (diabetes indication) instead of Zepbound. If you don't have diabetes, insurance won't cover it. Consider compounded tirzepatide.

Situation 2: You're on Medicare. Medicare Part D covers Mounjaro for diabetes but is prohibited by federal law from covering medications prescribed for weight loss, even if you have obesity-related comorbidities. This is the Medicare Part D coverage gap for weight-loss drugs, unchanged since 2003.

What to do: If you have diabetes, Mounjaro is covered (with high copay). If you need tirzepatide for weight loss only, Medicare won't pay. Out-of-pocket options: Lilly's patient assistance program (income-based, free medication if you qualify), compounded tirzepatide, or cash-pay brand name at $940 to $1,200/month.

Situation 3: You don't meet the BMI threshold. If your BMI is under 27, no commercial plan will cover Zepbound. If your BMI is 27 to 30 and you don't have a documented weight-related comorbidity, coverage is unlikely.

What to do: Work with your provider to document comorbidities if they exist (even mild hypertension or borderline lipids can qualify). If your BMI is genuinely under 27 and you're metabolically healthy, insurance appropriately won't cover a weight-loss medication.

Situation 4: Your A1C is too low for diabetes medication coverage. If your A1C is under 6.5%, you don't meet the diagnostic threshold for type 2 diabetes, and Mounjaro won't be covered. If your A1C is 6.5% to 7.0%, some plans cover it, others don't.

What to do: If you're prediabetic (A1C 5.7% to 6.4%) and your provider believes tirzepatide is appropriate for diabetes prevention, insurance won't pay. This is an off-label use. Consider compounded tirzepatide or wait until your A1C crosses 6.5% (not a medically sound strategy, but it's the coverage reality).

The compounded tirzepatide alternative for denied patients

When insurance denies coverage or the copay is unaffordable, compounded tirzepatide becomes the most common path to treatment.

Pricing comparison:

Option	Monthly cost	Insurance required?	FDA-approved?
Mounjaro (brand, with insurance + savings card)	$25 to $150	Yes	Yes
Mounjaro (brand, cash pay)	$940 to $1,200	No	Yes
Zepbound (brand, with insurance + savings card)	$25 to $150	Yes	Yes
Zepbound (brand, cash pay)	$940 to $1,200	No	Yes
Compounded tirzepatide (FormBlends)	$179 to $299	No	No
Compounded tirzepatide (other telehealth)	$199 to $499	No	No

Key differences:

• Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription.
• It's drawn from a vial with a syringe rather than delivered via a pre-filled pen.
• Dosing flexibility: compounding pharmacies can prepare custom doses not available in brand-name formulations.
• No insurance involvement, no prior authorization, no formulary restrictions.

When compounded makes sense:

• Your insurance denied coverage and appeals failed.
• Your copay is over $200/month even with the savings card.
• You're on Medicare and need tirzepatide for weight loss.
• You want predictable monthly pricing without insurance paperwork.

When brand-name makes more sense:

• Your insurance covers it and your copay is under $100/month.
• You strongly prefer FDA-approved medications.
• You want the convenience of a pre-filled pen.
• You qualify for Lilly's patient assistance program (free brand-name medication for low-income patients).

The decision should be made with a licensed provider who understands your medical history, insurance situation, and preferences.

How to check your specific coverage in 10 minutes

Step 1: Log into your insurance member portal. Most insurance companies have online portals where you can search the formulary. Look for "prescription drug list" or "formulary search."

Step 2: Search for "tirzepatide," "Mounjaro," and "Zepbound." Check if each is listed. Note the tier (Tier 1, 2, 3, 4, specialty). Check if "PA required" or "Step therapy required" is marked.

Step 3: Read the coverage criteria. Many portals link to the specific prior authorization criteria. Look for a PDF titled something like "Mounjaro Prior Authorization Criteria." This document lists exactly what your plan requires (A1C threshold, previous medications, BMI requirements).

Step 4: Call the number on your insurance card. Ask: "Does my plan cover Mounjaro for type 2 diabetes?" and "Does my plan cover Zepbound for weight management?" Ask about the copay tier and whether PA is required.

Step 5: Ask your provider's office to run a benefits check. Most provider offices can submit an electronic benefits verification before writing the prescription. This tells you your exact copay and whether PA is required. This is free and takes about 10 minutes.

This five-step process prevents the most common surprise: getting a prescription, submitting the PA, waiting two weeks, then learning your plan doesn't cover weight-loss medications at all.

The FormBlends Three-Path Decision Model

When a patient asks "How do I get tirzepatide covered by insurance?" the answer depends on which of three paths they're on. We call this the Three-Path Decision Model, and it's how our provider network triages new patient consultations.

Path A: Clear diabetes indication.

• Type 2 diabetes diagnosis (A1C over 6.5%)
• Failed metformin or metformin-intolerant
• Commercial insurance or Medicare Part D
• Action: Submit PA for Mounjaro. Approval probability: 60-75%. If approved, use Lilly savings card to reduce copay to $25-50. If denied, appeal with peer-to-peer review.

Path B: Weight-loss indication, insurance covers weight-loss drugs.

• BMI over 30, or BMI 27-30 with comorbidity
• Commercial insurance that includes weight-loss medications in formulary (check Step 1 above)
• Documented lifestyle interventions
• Action: Submit PA for Zepbound. Approval probability: 40-55%. If approved, use Lilly savings card. If denied, appeal with additional comorbidity documentation.

Path C: Insurance won't cover or patient denied after appeals.

• Plan excludes weight-loss medications, or
• Medicare patient needing weight-loss indication, or
• Denied PA after appeals exhausted, or
• Copay unaffordable even with savings card
• Action: Evaluate compounded tirzepatide. No PA required. Flat monthly pricing. Treatment starts within 3-5 days of provider consultation.

About 40% of patients who contact FormBlends are on Path C. They've already been denied or they know their insurance won't cover it. The remaining 60% are split between Path A (diabetes, high approval odds) and Path B (weight loss, lower approval odds, many discover their plan doesn't cover it).

[Diagram suggestion: Flowchart showing the three paths with decision points, approval probabilities, and alternative routes when denied. Use color coding: green for Path A (highest approval), yellow for Path B (moderate approval), red for Path C (insurance not an option).]

FAQ

How do I get tirzepatide covered by insurance? You need a qualifying diagnosis (type 2 diabetes for Mounjaro or obesity for Zepbound), a prescription from a licensed provider, and prior authorization approval from your insurance company. The PA requires medical records, lab results, and documentation of previous treatments. Approval takes 3 to 14 days and succeeds in 62% of diabetes cases and 41% of weight-loss cases.

What diagnosis do I need for insurance to cover tirzepatide? For Mounjaro, you need type 2 diabetes (A1C over 6.5%). For Zepbound, you need obesity (BMI over 30) or overweight (BMI 27-30) with at least one weight-related comorbidity like hypertension, dyslipidemia, or sleep apnea. The diagnosis must match the product.

Does insurance cover tirzepatide for weight loss? Only 28% of commercial insurance plans cover GLP-1 medications for weight loss as of 2026. Medicare does not cover weight-loss medications by federal law. If your plan covers Zepbound, prior authorization is required and approval rates are around 41%.

How long does tirzepatide prior authorization take? The median time is 8 business days. Urgent requests are supposed to be reviewed within 72 hours. If the PA is missing documentation, the insurance company requests additional information, which adds 3 to 7 days.

What happens if my tirzepatide PA is denied? You can appeal through three levels: peer-to-peer review (34% success rate), formal written appeal (22% success rate), and external independent review (18% success rate). Alternatively, you can pay cash for brand-name tirzepatide ($940 to $1,200/month) or switch to compounded tirzepatide ($179 to $499/month).

Does the Lilly savings card work with insurance? Yes, but only if you have commercial insurance that already covers the medication. The card reduces your copay to as low as $25/month. It does not work for Medicare, Medicaid, cash-pay patients, or patients whose insurance doesn't cover tirzepatide at all.

Can I get tirzepatide covered if I have prediabetes? Unlikely. Prediabetes (A1C 5.7% to 6.4%) doesn't meet the diagnostic threshold for type 2 diabetes, so Mounjaro won't be covered for diabetes treatment. Zepbound might be covered if your BMI is over 30 and your plan covers weight-loss medications, but prediabetes alone isn't sufficient.

Does Medicare cover tirzepatide? Medicare Part D covers Mounjaro for type 2 diabetes with prior authorization. Copays are typically $200 to $500/month on specialty tier. Medicare does not cover tirzepatide for weight loss under any circumstances due to federal law prohibiting Medicare coverage of weight-loss drugs.

What's the difference between Mounjaro and Zepbound for insurance? They contain the same active ingredient (tirzepatide) but have different FDA approvals. Mounjaro is approved for type 2 diabetes and covered under diabetes medication rules. Zepbound is approved for weight management and covered under weight-loss medication rules (if covered at all). Insurance treats them as completely separate drugs.

How much does tirzepatide cost with insurance? With insurance and prior authorization approval, copays range from $25 to $500/month depending on your plan's tier structure. The Lilly savings card reduces most commercial insurance copays to $25 to $50/month. Without insurance, cash price is $940 to $1,200/month.

Can my doctor help me get tirzepatide covered? Yes. Your provider submits the prior authorization with supporting documentation. If denied, your provider can request a peer-to-peer review to discuss your case with the insurance company's physician. Providers experienced with tirzepatide PAs have higher approval rates because they know which documentation elements matter most.

What if my insurance doesn't cover weight-loss medications at all? If your plan has a blanket exclusion for weight-loss drugs, no amount of medical documentation will change that. Your options are: get a diabetes diagnosis if you qualify (A1C over 6.5%) and switch to Mounjaro, pay cash for brand-name Zepbound ($940 to $1,200/month), or use compounded tirzepatide ($179 to $499/month).

Sources

1. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
2. IQVIA Institute for Human Data Science. GLP-1 Receptor Agonist Utilization and Access Report. IQVIA. 2025.
3. MMIT (Managed Markets Insight & Technology). Prior Authorization Trends in Specialty Pharmacy. MMIT. 2025.
4. Sattar N et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. New England Journal of Medicine. 2024.
5. CoverMyMeds. Prior Authorization Approval and Appeal Rates 2025. CoverMyMeds. 2025.
6. Eli Lilly and Company. Mounjaro Prescribing Information. Lilly USA. 2024.
7. Eli Lilly and Company. Zepbound Prescribing Information. Lilly USA. 2023.
8. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. CMS. 2025.
9. Rosenbaum L et al. The challenge of specialty drug access: prior authorization in the GLP-1 era. Health Affairs. 2025.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
11. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS clinical trial program. Diabetes Care. 2023.
12. National Association of Insurance Commissioners. Model Regulation for Prescription Drug Prior Authorization. NAIC. 2024.
13. Academy of Managed Care Pharmacy. Prior Authorization Reform: Current State and Future Directions. AMCP. 2025.
14. U.S. Food and Drug Administration. Tirzepatide Approval History and Postmarket Requirements. FDA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and tirzepatide are trademarks of Eli Lilly and Company. Medicare, Medicaid, and TRICARE are U.S. government programs. UnitedHealthcare, Aetna, Cigna, BlueCross BlueShield, CVS Caremark, Express Scripts, and OptumRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.